Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
NEXTHERA CAPITAL LP (CIK 1646343) reported $120.1M across 23 reported positions in its SEC 13F filing for 2019-06-30. Largest positions: ICPT ($12.1M, 10.10%), INSM ($12.1M, 10.04%), BOLD1 ($11.1M, 9.27%), NBIX ($7.8M, 6.50%), SRPT ($7.6M, 6.37%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ICPT | Intercept Pharmaceuticals Inc | $12.1M | 10.10% | 152,441 | Added |
| 2 | INSM | Insmed Inc | $12.1M | 10.04% | 470,741 | Added |
| 3 | BOLD1 | Audentes Therapeutics Inc | $11.1M | 9.27% | 294,013 | Added |
| 4 | NBIX | Neurocrine Biosciences Inc | $7.8M | 6.50% | 92,380 | Added |
| 5 | SRPT | Sarepta Therapeutics Inc | $7.6M | 6.37% | 50,317 | Added |
| 6 | GBT | Global Blood Therapeutics Inc | $7.5M | 6.23% | 142,305 | Added |
| 7 | IMMU | Immunomedics Inc | $7.3M | 6.06% | 524,140 | Added |
| 8 | CHRS | Coherus Biosciences Inc | $7.0M | 5.82% | 316,316 | New |
| 9 | ASND | Ascendis Pharma A/S | $6.9M | 5.78% | 60,266 | New |
| 10 | PCRX | Pacira BioSciences Inc | $6.5M | 5.40% | 149,086 | New |
| 11 | URGN | UroGen Pharma Ltd | $6.4M | 5.29% | 176,866 | Added |
| 12 | QURE | uniQure NV | $4.7M | 3.90% | 59,883 | Added |
| 13 | AMRN | Amarin Corp PLC | $4.5M | 3.72% | 230,295 | Added |
| 14 | ABBV | AbbVie Inc | $3.8M | 3.19% | 52,681 | New |
| 15 | BHVN1 | Biohaven Pharmaceutical Holdin | $3.8M | 3.14% | 86,165 | New |
| 16 | VTRS | Mylan NV | $2.0M | 1.63% | 102,560 | New |
| 17 | ITCI | Intra-Cellular Therapies Inc | $1.9M | 1.55% | 143,665 | New |
| 18 | REGN | Regeneron Pharmaceuticals Inc | $1.8M | 1.48% | 5,668 | New |
| 19 | MDGL | Madrigal Pharmaceuticals Inc | $1.6M | 1.35% | 15,423 | Added |
| 20 | DERM2 | Dermira Inc | $1.3M | 1.10% | 138,102 | New |
| 21 | GILD | Gilead Sciences Inc | $1.3M | 1.05% | 18,697 | New |
| 22 | ANAB | AnaptysBio Inc | $679,000 | 0.57% | 12,026 | New |
| 23 | AGN | Allergan PLC | $560,000 | 0.47% | 3,347 | Trimmed |
| 24 | ACORQ | Acorda Therapeutics Inc | $0 | 0.00% | 0 | Exited |
| 25 | BHC | Bausch Health Cos Inc | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2019-06-30